|[January 18, 2013]
Research and Markets: Hyperinsulinemia - Pipeline Review, H2 2012 Covers Key Discontinued Pipeline Projects
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/pqwvr8/hyperinsulinemia)
has announced the addition of Global Markets Direct's new report
"Hyperinsulinemia - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Hyperinsulinemia - Pipeline Review, H2 2012',
provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for
Hyperinsulinemia, complete with latest updates, and special features on
late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Hyperinsulinemia
Hyperinsulinemia - Pipeline Review, Half Year is built using data and
information sourced from Global Markets Direct's proprietary databases,
Company/University websites, SEC (News - Alert) filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets
- A snapshot of the global therapeutic scenario for Hyperinsulinemia.
- A review of the Hyperinsulinemia products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging
from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
- Coverage of the Hyperinsulinemia pipeline on the basis of route of
administration and molecule type.
- Latest news and deals relating to the products.
For more information visit http://www.researchandmarkets.com/research/pqwvr8/hyperinsulinemia
Source (News - Alert): Global Markets Direct
[ Back To Cloud Contact Center's Homepage ]